Treatment of Kodamaea ohmeri Infection
Treat Kodamaea ohmeri infections with an echinocandin as first-line therapy (caspofungin 70 mg loading dose then 50 mg daily, micafungin 100 mg daily, or anidulafungin 200 mg loading dose then 100 mg daily), following the same approach as for invasive candidiasis.
Rationale and Clinical Approach
Kodamaea ohmeri (formerly Pichia ohmeri) is a rare yeast pathogen that is taxonomically related to Candida species but represents an emerging pathogen not specifically addressed in current guidelines 1. However, the most recent global candidiasis guidelines from 2025 acknowledge the importance of managing emerging pathogens and recommend applying invasive candidiasis treatment principles to related yeasts 1.
Initial Treatment Strategy
Start with an echinocandin as your first-line agent, mirroring the approach for candidemia and invasive candidiasis 2
- Caspofungin: 70 mg loading dose, then 50 mg daily
- Micafungin: 100 mg daily
- Anidulafungin: 200 mg loading dose, then 100 mg daily
Obtain susceptibility testing immediately upon identification, as K. ohmeri can exhibit variable azole susceptibility patterns
Alternative Agents Based on Clinical Context
If echinocandins cannot be used:
Liposomal amphotericin B 3-5 mg/kg daily is an effective alternative, though less attractive due to toxicity potential 2
Fluconazole 400-800 mg (6-12 mg/kg) daily can be considered ONLY if:
- The patient is not critically ill
- Susceptibility testing confirms susceptibility
- No prior azole exposure
- Clinical stability is established 2
Duration and Monitoring
- Continue therapy for at least 2 weeks after documented clearance from bloodstream and resolution of symptoms 2
- Obtain follow-up cultures every 1-2 days to establish clearance 2
- Remove central venous catheters early if present and safely removable 2
- Perform dilated funduscopic examination within the first week in non-neutropenic patients to rule out endophthalmitis 2
Critical Pitfalls to Avoid
Do not assume azole susceptibility - K. ohmeri may have intrinsic or acquired resistance to fluconazole, making empiric azole therapy potentially inadequate. Always obtain susceptibility data.
Do not delay catheter removal - If a central line is the presumed source, early removal significantly improves outcomes, just as with Candida species 2.
Do not use fluconazole monotherapy in critically ill patients - Even if susceptible, echinocandins have superior outcomes in severe infections 2.
The 2025 ECMM/ISHAM/ASM global guidelines emphasize that emerging pathogens like K. ohmeri require the same aggressive approach as established Candida species, with echinocandins providing the broadest activity and best safety profile 1.